Host: |
E. coli |
Reactivity: |
Human |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Recombinant-Human IL-1RN-C-His protein was developed from e. coli and has a target region of C-His. For use in research applications. |
Formulation: |
Lyophilized from a 0.22 Mu m filtered solution of PBS, pH 7.4. Contact us for customized product form or formulation. |
Immunoreactivity: |
Measured by its binding ability in a functional ELISA. Immobilized Recombinant Human IL1RN at 10 Mu g/mL (100 Mu L/well) can bind Recombinant Human IL1R2 with a linear range of 0.4-1.8 Mu g/mL. |
Gene Symbol: |
IL1RN |
Gene ID: |
3557 |
Uniprot ID: |
IL1RA_HUMAN |
Immunogen Region: |
Arg26-Glu177 |
Immunogen: |
Recombinant Human IL-1RN Protein is produced by E. coli expression system. The target protein is expressed with sequence (Arg26-Glu177) of human IL-1RN (Accession #NP_776214.1) fused with an initial Met at the N-terminus and a 6×His tag at the C-term |
Tissue Specificity | The intracellular form of IL1RN is predominantly expressed in epithelial cells. |
Function | Anti-inflammatory antagonist of interleukin-1 family of proinflammatory cytokines such as interleukin-1beta/IL1B and interleukin-1alpha/IL1A. Protects from immune dysregulation and uncontrolled systemic inflammation triggered by IL1 for a range of innate stimulatory agents such as pathogens. |
Protein Name | Interleukin-1 Receptor Antagonist ProteinIl-1rnIl-1raIrapIcil-1raIl1 InhibitorAnakinra |
Database Links | Reactome: R-HSA-6783783Reactome: R-HSA-9020702 |
Cellular Localisation | Isoform 1: SecretedIsoform 2: CytoplasmIsoform 3: CytoplasmIsoform 4: Cytoplasm |
Alternative Protein Names | Interleukin-1 Receptor Antagonist Protein proteinIl-1rn proteinIl-1ra proteinIrap proteinIcil-1ra proteinIl1 Inhibitor proteinAnakinra proteinIL1RN proteinIL1F3 proteinIL1RA protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance